Chronic Fatigue Syndrome Clinical Trial
Official title:
A Complex Intervention for a Complex Symptom - a Randomized Controlled Trial in Chronically Fatigued Lymphoma Survivors
Verified date | April 2024 |
Source | Oslo University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The present study is a randomized controlled trial (RCT) with an overall objective to examine the effect of an interdisciplinary complex intervention on the level of fatigue in lymphoma survivors with chronic fatigue. Secondary aims are to examine the effects of the intervention on daily functioning, work status/ability, physical fitness and QoL among the survivors, on QoL of their relatives and on the societal costs.The intervention will last for 12+12 weeks and include four components; patient education, supervised physical exercise, cognitive behavioral program and nutritional counselling. Outcomes will be assessed at baseline,post-intervention (12 weeks after baseline) and at 3-month, 6-month, 12-month and 24-month follow-up after completed intervention.
Status | Active, not recruiting |
Enrollment | 150 |
Est. completion date | June 30, 2025 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Survivors of Hodgkin and aggressive non-Hodgkin lymphoma - Not indolent non-Hodgkin lymphoma - Not CNS lymphoma at diagnosis - Not second cancer - Not ongoing cancer treatment - Chronic fatigue measured by Chalder Fatigue Questionnaire - Diagnosed 2010-2020 - Received treatment with curative intent - 18 - 70 years old at inclusion - > 2 years since last treatment - Able to understand the Norwegian language - Participation approval from oncologist in the project group Exclusion Criteria: - Persisting fatigue > 1 year before the cancer diagnosis - Somatic/physical conditions (i.e. severe heart failure/disease, lung disease, use of wheelchair /crutches) - Psychiatric or mental disorders (i.e. dementia, severe depression, schizophrenia) - Use of stimulants for ADHD - Substance abuse disorder |
Country | Name | City | State |
---|---|---|---|
Norway | Oslo University Hospital | Oslo |
Lead Sponsor | Collaborator |
---|---|
Oslo University Hospital | Diakonhjemmet Hospital, Norwegian School of Sport Sciences, Norwegian University of Science and Technology, St. Olavs Hospital, UiT The Arctic University of Norway, University of Alberta, University of Oslo |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in change in fatigue levels (physical-, mental- and total fatigue) between intervention and control group, assessed by the Chalder Fatigue Questionnaire | The Fatigue Questionnaire consists of 11 questions, distributed on a physical fatigue scale (7 items) and mental fatigue scale (4 items) Each item is scored from 0 to 3. This provides a physical fatigue score from 0 to 21, mental fatigue score from 0 to 12, and total score from 0 to 33. Higher score implies more fatigue. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in fatigue levels between groups assessed by Chalder Fatigue Questionnaire | The Fatigue Questionnaire consists of 11 questions, distributed on a physical fatigue scale (7 items) and mental fatigue scale (4 items) Each item is scored from 0 to 3, providing a total score from 0 to 33. Higher score implies more fatigue. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in fatigue levels between groups assessed by Chalder Fatigue Questionnaire | The Fatigue Questionnaire consists of 11 questions, distributed on a physical fatigue scale (7 items) and mental fatigue scale (4 items) Each item is scored from 0 to 3, providing a total score from 0 to 33. Higher score implies more fatigue. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Change in fatigue levels among all participants assessed by Chalder Fatigue Questionnaire | The Fatigue Questionnaire consists of 11 questions, distributed on a physical fatigue scale (7 items) and mental fatigue scale (4 items) Each item is scored from 0 to 3, providing a total score from 0 to 33. Higher score implies more fatigue. | From post-intervention (T1) to 12-month follow-up (T4) | |
Secondary | Change in fatigue levels among all participants assessed by Chalder Fatigue Questionnaire | The Fatigue Questionnaire consists of 11 questions, distributed on a physical fatigue scale (7 items) and mental fatigue scale (4 items) Each item is scored from 0 to 3, providing a total score from 0 to 33. Higher score implies more fatigue. | From post-intervention (T1) to 24-month follow-up (T5) | |
Secondary | Difference in change in daily functioning between groups assessed by European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes five functioning scales (physical, role, cognitive, emotional and social).All of the scales range in score from 0 to 100.
A high score for a functional scale represents a high / healthy level of functioning. |
From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in daily functioning between groups assessed by European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes five functioning scales (physical, role, cognitive, emotional and social).All of the scales range in score from 0 to 100.
A high score for a functional scale represents a high / healthy level of functioning. |
From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in daily functioning between groups assessed by European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes five functioning scales (physical, role, cognitive, emotional and social).All of the scales range in score from 0 to 100.
A high score for a functional scale represents a high / healthy level of functioning. |
From baseline (T0) to 36 weeks (T3) | |
Secondary | Change in daily functioning among all participants assessed by European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes five functioning scales (physical, role, cognitive, emotional and social).All of the scales range in score from 0 to 100.
A high score for a functional scale represents a high / healthy level of functioning. |
From post-intervention (T1) to 12-month follow-up (T4) | |
Secondary | Change in daily functioning among all participants assessed by European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes five functioning scales (physical, role, cognitive, emotional and social).All of the scales range in score from 0 to 100.
A high score for a functional scale represents a high / healthy level of functioning. |
From post-intervention (T1) to 24-month follow-up (T5) | |
Secondary | Difference in change in global quality of life between groups assessed by European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes a global health status / quality of life (QoL) scale, which range in score from 0 to 100. A high score for the global health status / QoL represents a high QoL. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in global quality of life between groups assessed by European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes a global health status / quality of life (QoL) scale, which range in score from 0 to 100. A high score for the global health status / QoL represents a high QoL. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in global quality of life between groups assessed by European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes a global health status / quality of life (QoL) scale, which range in score from 0 to 100. A high score for the global health status / QoL represents a high QoL. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Change in global quality of life among all participants assessed by European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes a global health status / quality of life (QoL) scale, which range in score from 0 to 100. A high score for the global health status / QoL represents a high QoL. | From post-intervention (T1) to 12-month follow-up (T4) | |
Secondary | Change in global quality of life among all participants assessed by European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes a global health status / quality of life (QoL) scale, which range in score from 0 to 100. A high score for the global health status / QoL represents a high QoL. | From post-intervention (T1) to 24-month follow-up (T5) | |
Secondary | Difference in change in work status between groups assessed by questions from the HUNT4-study | Participants are asked to report their current work status | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in work status between groups assessed by questions from the HUNT4-study | Participants are asked to report their current work status | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in work status between groups assessed by questions from the HUNT4-study | Participants are asked to report their current work status | From baseline (T0) to 36 weeks (T3) | |
Secondary | Change in work status in both groups assessed by questions from the HUNT4-study | Participants are asked to report their current work status | From post-intervention (T1) to 12 months follow-up (T4) | |
Secondary | Change in work status in both groups assessed by questions from the HUNT4-study | Participants are asked to report their current work status | From post-intervention (T1) to 24 months follow-up (T5) | |
Secondary | Difference in change in work ability between groups assessed by the Work Ability Index scale | Current work ability is rated compared with the lifetime best on a scale from 0 to 10. Higher score implies higher work ability. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in work ability between groups assessed by the Work Ability Index scale | Current work ability is rated compared with the lifetime best on a scale from 0 to 10. Higher score implies higher work ability. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in work ability between groups assessed by the Work Ability Index scale | Current work ability is rated compared with the lifetime best on a scale from 0 to 10. Higher score implies higher work ability. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Change in work ability in both groups assessed by the Work Ability Index scale | Current work ability is rated compared with the lifetime best on a scale from 0 to 10. Higher score implies higher work ability. | From post-intervention (T1) to 12 months follow-up (T4) | |
Secondary | Change in work ability in both groups assessed by the Work Ability Index scale | Current work ability is rated compared with the lifetime best on a scale from 0 to 10. Higher score implies higher work ability. | From post-intervention (T1) to 24 months follow-up (T5) | |
Secondary | Difference in change in work ability between groups assessed by the Work Ability Index: physical demands of the job | Assessed by rating work ability in relation to the physical demands of the job, by the following response alternatives: very good, rather good, moderate, rather poor or very poor | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in work ability between groups assessed by the Work Ability Index: physical demands of the job | Assessed by rating work ability in relation to the physical demands of the job, by the following response alternatives: very good, rather good, moderate, rather poor or very poor | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in work ability between groups assessed by the Work Ability Index: physical demands of the job | Assessed by rating work ability in relation to the physical demands of the job, by the following response alternatives: very good, rather good, moderate, rather poor or very poor | From baseline (T0) to 36 weeks (T3) | |
Secondary | Change in work ability in both groups assessed by the Work Ability Index: physical demands of the job | Assessed by rating work ability in relation to the physical demands of the job, by the following response alternatives: very good, rather good, moderate, rather poor or very poor | From post-intervention (T1) to 12 months follow-up (T4) | |
Secondary | Change in work ability in both groups assessed by the Work Ability Index: physical demands of the job | Assessed by rating work ability in relation to the physical demands of the job, by the following response alternatives: very good, rather good, moderate, rather poor or very poor | From post-intervention (T1) to 24 months follow-up (T5) | |
Secondary | Difference in change in work ability between groups assessed by the Work Ability Index: psychological demands of the job | Assessed by rating work ability in relation to the psychological demands of the job, by the following response alternatives: very good, rather good, moderate, rather poor or very poor | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in work ability between groups assessed by the Work Ability Index: psychological demands of the job | Assessed by rating work ability in relation to the psychological demands of the job, by the following response alternatives: very good, rather good, moderate, rather poor or very poor | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in work ability between groups assessed by the Work Ability Index: psychological demands of the job | Assessed by rating work ability in relation to the psychological demands of the job, by the following response alternatives: very good, rather good, moderate, rather poor or very poor | From baseline (T0) to 36 weeks (T3) | |
Secondary | Change in work ability in both groups assessed by the Work Ability Index: psychological demands of the job | Assessed by rating work ability in relation to the psychological demands of the job, by the following response alternatives: very good, rather good, moderate, rather poor or very poor | From post-intervention (T1) to 12 months follow-up (T4) | |
Secondary | Change in work ability in both groups assessed by the Work Ability Index: psychological demands of the job | Assessed by rating work ability in relation to the psychological demands of the job, by the following response alternatives: very good, rather good, moderate, rather poor or very poor | From post-intervention (T1) to 24 months follow-up (T5) | |
Secondary | Difference in change in cardiorespiratory fitness between groups assessed by cardio-pulmonary exercise testing (CPET) | Peak oxygen uptake (VO2peak) is measured | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in cardiorespiratory fitness between groups assessed by cardio-pulmonary exercise testing (CPET) | Peak oxygen uptake (VO2peak) is measured | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in cardiorespiratory fitness between groups assessed by cardio-pulmonary exercise testing (CPET) | Peak oxygen uptake (VO2peak) is measured | From baseline (T0) to 36 weeks (T3) | |
Secondary | Difference in change in cardiorespiratory fitness between groups assessed by a treadmill test | In cases where participants do not have the opportunity to travel for physical fitness tests, cardiorespiratory fitness will be assessed by an indirect treadmill test (modified Balke protocol) at their local physiotherapist. Time to exhaustion will be used as an indicator of cardiorespiratory fitness. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in cardiorespiratory fitness between groups assessed by a treadmill test | In cases where participants do not have the opportunity to travel for physical fitness tests, cardiorespiratory fitness will be assessed by an indirect treadmill test (modified Balke protocol) at their local physiotherapist. Time to exhaustion will be used as an indicator of cardiorespiratory fitness. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in cardiorespiratory fitness between groups assessed by a treadmill test | In cases where participants do not have the opportunity to travel for physical fitness tests, cardiorespiratory fitness will be assessed by an indirect treadmill test (modified Balke protocol) at their local physiotherapist. Time to exhaustion will be used as an indicator of cardiorespiratory fitness. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Difference in change in lower body muscle strength between groups assessed by leg press | The one-repetition maximum (1RM) test (the maximal workload that can be lifted once)) in leg press. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in lower body muscle strength between groups assessed by leg press | The one-repetition maximum (1RM) test (the maximal workload that can be lifted once)) in leg press. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in lower body muscle strength between groups assessed by leg press | The one-repetition maximum (1RM) test (the maximal workload that can be lifted once)) in leg press. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Difference in change in lower body muscle strength between groups assessed by push-ups | The maximum number of push-ups that can be performed in one set | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in upper body muscle strength between groups assessed by push-ups | The maximum number of push-ups that can be performed in one set | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in upper body muscle strength between groups assessed by push-ups | The maximum number of push-ups that can be performed in one set | From baseline (T0) to 36 weeks (T3) | |
Secondary | Difference in change in level of depressive symptoms between groups assessed by the Patient Health Questionnaire-9 | Each of the 9 items is scored from 0-3, providing a total score from 0 to 27. A higher score implies higher level of depressive symptoms. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in level of depressive symptoms between groups assessed by the Patient Health Questionnaire-9 | Each of the 9 items is scored from 0-3, providing a total score from 0 to 27. A higher score implies higher level of depressive symptoms. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in level of depressive symptoms between groups assessed by the Patient Health Questionnaire-9 | Each of the 9 items is scored from 0-3, providing a total score from 0 to 27. A higher score implies higher level of depressive symptoms. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Change in level of depressive symptoms among all participants assessed by the Patient Health Questionnaire-9 | Each of the 9 items is scored from 0-3, providing a total score from 0 to 27. A higher score implies higher level of depressive symptoms. | From post-intervention (T1) to 12-month follow-up (T4) | |
Secondary | Change in level of depressive symptoms among all participants assessed by the Patient Health Questionnaire-9 | Each of the 9 items is scored from 0-3, providing a total score from 0 to 27. A higher score implies higher level of depressive symptoms. | From post-intervention (T1) to 24-month follow-up (T5) | |
Secondary | Difference in change in level of anxiety symptoms between groups assessed by the General Anxiety Disorder 7-items (GAD7). | Each of the 7 items is scored from 0-3, providing a total score from 0-21. A higher score implies higher level of anxiety symptoms. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in level of anxiety symptoms between groups assessed by the General Anxiety Disorder 7-items (GAD7). | Each item is scored from 0-3, providing a total score from 0-21. A higher score implies higher level of anxiety symptoms. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in level of anxiety symptoms between groups assessed by the General Anxiety Disorder 7-items (GAD7). | Each of the 7 items is scored from 0-3, providing a total score from 0-21. A higher score implies higher level of anxiety symptoms. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Change in level of anxiety symptoms in all participants assessed by the General Anxiety Disorder 7-items (GAD7). | Each of the 7 items is scored from 0-3, providing a total score from 0-21. A higher score implies higher level of anxiety symptoms. | From baseline (T0) to 12 months follow-up weeks (T4) | |
Secondary | Change in level of anxiety symptoms in all participants assessed by the General Anxiety Disorder 7-items (GAD7). | Each of the 7 items is scored from 0-3, providing a total score from 0-21. A higher score implies higher level of anxiety symptoms. | From baseline (T0) to 24 months follow-up weeks (T5) | |
Secondary | Difference in change in sense of exercise competence between groups assessed by the Perceived Competence Scale. | The scale consists of 4 items, each scored from 1 (totally disagree) to 7 (totally agree). A sum score from 0 to 7 is calculated based on the mean score of the items, with increasing score implying higher exercise competence. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in sense of exercise competence between groups assessed by the Perceived Competence Scale. | The scale consists of 4 items, each scored from 1 (totally disagree) to 7 (totally agree). A sum score from 0 to 7 is calculated based on the mean score of the items, with increasing score implying higher exercise competence. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in sense of exercise competence between groups assessed by the Perceived Competence Scale. | The scale consists of 4 items, each scored from 1 (totally disagree) to 7 (totally agree). A sum score from 0 to 7 is calculated based on the mean score of the items, with increasing score implying higher exercise competence. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Change in sense of exercise competence in both groups assessed by the Perceived Competence Scale. | The scale consists of 4 items, each scored from 1 (totally disagree) to 7 (totally agree). A sum score from 0 to 7 is calculated based on the mean score of the items, with increasing score implying higher exercise competence. | From post-intervention (T1) to 12 months follow-up (T4) | |
Secondary | Change in sense of exercise competence in both groups assessed by the Perceived Competence Scale. | The scale consists of 4 items, each scored from 1 (totally disagree) to 7 (totally agree). A sum score from 0 to 7 is calculated based on the mean score of the items, with increasing score implying higher exercise competence. | From post-intervention (T1) to 24 months follow-up (T5) | |
Secondary | Difference in change in satisfaction with life between groups assessed by the Satisfaction With Life Scale. | The scale consists of 5 items, each scored from 1 (totally disagree) to 7 (totally agree). A sum score from 5 to 35 is calculated, with increasing score implying higher satisfaction with life. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in satisfaction with life between groups assessed by the Satisfaction With Life Scale. | The scale consists of 5 items, each scored from 1 (totally disagree) to 7 (totally agree). A sum score from 5 to 35 is calculated, with increasing score implying higher satisfaction with life. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in satisfaction with life between groups assessed by the Satisfaction With Life Scale. | The scale consists of 5 items, each scored from 1 (totally disagree) to 7 (totally agree). A sum score from 5 to 35 is calculated, with increasing score implying higher satisfaction with life. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Difference in change in sense of vitality between groups assessed by the Subjective Vitality Scale | The scale consists of 5 items, each scored from 1 (totally disagree) to 7 (totally agree). A sum score from 5 to 35 is calculated, with increasing score implying higher sense of vitality. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in sense of vitality between groups assessed by the Subjective Vitality Scale | The scale consists of 5 items, each scored from 1 (totally disagree) to 7 (totally agree). A sum score from 5 to 35 is calculated, with increasing score implying higher sense of vitality. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in sense of vitality between groups assessed by the Subjective Vitality Scale | The scale consists of 5 items, each scored from 1 (totally disagree) to 7 (totally agree). A sum score from 5 to 35 is calculated, with increasing score implying higher sense of vitality. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Difference in change in adherence to the Norwegian food-based dietary guidelines between groups assessed by DIGIKOST-FFQ | DIGIKOST-FFQ is a food frequency questionnaire aiming to benchmark against the Norwegian food-based dietary guidelines. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in adherence to the Norwegian food-based dietary guidelines assessed by DIGIKOST-FFQ | DIGIKOST-FFQ is a food frequency questionnaire aiming to benchmark against the Norwegian food-based dietary guidelines. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in adherence to the Norwegian food-based dietary guidelines assessed by DIGIKOST-FFQ | DIGIKOST-FFQ is a food frequency questionnaire aiming to benchmark against the Norwegian food-based dietary guidelines. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Difference in change in general health between groups measured by European Quality of Life Five-Dimension Scale Questionnaire (EQ-5D) | EQ-5D consists of five dimensions (mobility, self-care, usual activities, pain & discomfort, anxiety & depression), each of which has five severity levels that are described by statements appropriate to that dimension. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in general health between groups measured by European Quality of Life Five-Dimension Scale Questionnaire (EQ-5D) | EQ-5D consists of five dimensions (mobility, self-care, usual activities, pain & discomfort, anxiety & depression), each of which has five severity levels that are described by statements appropriate to that dimension. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in general health between groups measured by European Quality of Life Five-Dimension Scale Questionnaire (EQ-5D) | EQ-5D consists of five dimensions (mobility, self-care, usual activities, pain & discomfort, anxiety & depression), each of which has five severity levels that are described by statements appropriate to that dimension. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Difference in change in quality of life among the relatives between groups measured by Research and Development 36-term Short Form Health Survey (RAND SF-36) | RAND-36 comprises 36 items that assess eight health concepts: physical functioning, role limitations caused by physical health problems, role limitations caused by emotional problems, social functioning, emotional well-being, energy/fatigue, pain, and general health perceptions. Physical and mental health summary scores are also derived from the eight RAND-36 scales.All questions are scored on a scale from 0 to 100, with 100 representing the highest level of functioning possible. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in quality of life among the relatives between groups measured by Research and Development 36-term Short Form Health Survey (RAND SF-36) | RAND-36 comprises 36 items that assess eight health concepts: physical functioning, role limitations caused by physical health problems, role limitations caused by emotional problems, social functioning, emotional well-being, energy/fatigue, pain, and general health perceptions. Physical and mental health summary scores are also derived from the eight RAND-36 scales.All questions are scored on a scale from 0 to 100, with 100 representing the highest level of functioning possible. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in quality of life among the relatives between groups measured by Research and Development 36-term Short Form Health Survey (RAND SF-36) | RAND-36 comprises 36 items that assess eight health concepts: physical functioning, role limitations caused by physical health problems, role limitations caused by emotional problems, social functioning, emotional well-being, energy/fatigue, pain, and general health perceptions. Physical and mental health summary scores are also derived from the eight RAND-36 scales.All questions are scored on a scale from 0 to 100, with 100 representing the highest level of functioning possible. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Difference in change in quality of life among the relatives between groups measured by the global health status / QoL scale from the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes a global health status / quality of life (QoL) scale, which range in score from 0 to 100. A high score for the global health status / QoL represents a high QoL. | From baseline (T0) to 12 weeks (T1) | |
Secondary | Difference in change in quality of life among the relatives between groups measured by the global health status / QoL scale from the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes a global health status / quality of life (QoL) scale, which range in score from 0 to 100. A high score for the global health status / QoL represents a high QoL. | From baseline (T0) to 24 weeks (T2) | |
Secondary | Difference in change in quality of life among the relatives between groups measured by the global health status / QoL scale from the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes a global health status / quality of life (QoL) scale, which range in score from 0 to 100. A high score for the global health status / QoL represents a high QoL. | From baseline (T0) to 36 weeks (T2) | |
Secondary | Difference in change in quality of life among the relatives between groups measured by the global health status / QoL scale from the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). | The questionnaire includes a global health status / quality of life (QoL) scale, which range in score from 0 to 100. A high score for the global health status / QoL represents a high QoL. | From baseline (T0) to 36 weeks (T3) | |
Secondary | Cost-effectiveness of the intervention, calculated based on measurements of health-related QoL and resource use (costs related to the intervention). | Combining information about health-related QoL will give quality-adjusted life-years, while valuation of resource use using standard principles of health economic evaluation will provide estimates of costs | From baseline (0) to 36 weeks (T3) | |
Secondary | Perceived benefits of the intervention components assessed by questions used in and modified from the PasOpp study from the Directorate of Health in Norway | Questions assessing benefits of the intervention | At 12- and 24-month follow-up | |
Secondary | Use of information, experiences, strategies and advices learned in the intervention program assessed by self-made questions | Questions assessing daily use of information, strategies and advices learned in the intervention program | At 12- and 24-month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05454683 -
Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT02075489 -
Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans
|
N/A | |
Completed |
NCT01686074 -
Motor Control in Chronic Fatigue Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT01651754 -
Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome
|
N/A | |
Completed |
NCT00540254 -
Behavioral Insomnia Therapy With Chronic Fatigue Syndrome
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00071162 -
Genetics of Fibromyalgia
|
N/A | |
Withdrawn |
NCT04870476 -
Feasibility and Acceptability of the Internet-delivered Treatment "One Step at the Time" for Bodily Distress Syndrome
|
N/A | |
Completed |
NCT05730660 -
Quercetin Phytosome® Chronic Fatigue Syndrome
|
N/A | |
Recruiting |
NCT04542161 -
Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
|
Phase 2 | |
Recruiting |
NCT03807973 -
Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.
|
Phase 1 | |
Recruiting |
NCT05719493 -
Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue Syndrome (SYNCHRONIZE +)
|
N/A | |
Recruiting |
NCT05967052 -
Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation
|
Phase 2 | |
Terminated |
NCT01730495 -
Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01156909 -
B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
|
Phase 2 | |
Completed |
NCT01650636 -
Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process
|
N/A | |
Completed |
NCT01046370 -
A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia
|
N/A | |
Completed |
NCT00100412 -
Hyporeactivity and Gulf War Illness
|
N/A | |
Recruiting |
NCT06128967 -
A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial
|
Phase 3 | |
Completed |
NCT02669212 -
Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health
|
N/A | |
Not yet recruiting |
NCT06011135 -
Exploring Worry in CFS/ME
|